Indivior PLC Notice of Results (0385O)
October 01 2019 - 1:01AM
UK Regulatory
TIDMINDV
RNS Number : 0385O
Indivior PLC
01 October 2019
Indivior to Announce 2019 Year-to-Date and Third Quarter Results
October 31st
Slough, UK, and Richmond, VA - 1 October 2019 - Indivior PLC
(LON: INDV) today announced that it will release its 2019
year-to-date and third quarter results on Thursday, October 31st at
11:00 London time (7:00 a.m. U.S. Eastern). The results will be
available via the London Stock Exchange Regulatory News Service
(RNS) and on the "Investors" section of the company's website at
www.indivior.com.
Key members of Indivior's leadership team led by Shaun Thaxter,
Chief Executive Officer, will host a conference call to discuss the
results and address questions from qualified analysts and investors
at 12:00 London time (8:00 a.m. U.S. Eastern) on October 31st.
Access the Live Results Webcast October 31st
The webcast event will be available on the "Investors" section
of the company's website at www.indivior.com. The webcast link is
https://edge.media-server.com/mmc/p/tcgvargq. Participants also may
access the results presentation telephonically: US participants
+1-631-510-7495; international participants +44(0)2071-928000.
Please reference confirmation number 7297368. A replay of the
presentation will be available at www.indivior.com.
About Indivior
Indivior is a global specialty pharmaceutical company with a
20-year legacy of leadership in patient advocacy and health policy
while providing education on evidence-based treatment models that
have revolutionized modern addiction treatment. Our vision is for
all patients around the world to have access to evidence-based
treatment for the chronic conditions and co-occurring disorders of
addiction. The name is the fusion of the words individual and
endeavor, and the tagline "Focus on you" makes the Company's
commitment clear. Indivior is dedicated to transforming addiction
from a global human crisis to a recognized and treated chronic
disease. Building on its global portfolio of opioid dependence
treatments, Indivior has a strong pipeline of product candidates
designed to both expand on its heritage in this category and
address other chronic conditions and co-occurring disorders of
addiction, including alcohol use disorder and schizophrenia.
Headquartered in the United States in Richmond, VA, Indivior
employs more than 800 individuals globally and its portfolio of
products is available in over 40 countries worldwide. Visit
www.indivior.com to learn more. Connect with Indivior on LinkedIn
by visiting www.linkedin.com/company/indivior.
Media Contacts:
US
IndiviorMediaContacts@indivior.com
+1 804-594-0836
UK
Tulchan Communications
+44 207-353-4200
Investor Contact:
Jason Thompson, Indivior
Vice President, Investor Relations
+1 804-402-7123
Jason.Thompson@indivior.com
-ends-
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOREANNXAEDNEFF
(END) Dow Jones Newswires
October 01, 2019 02:01 ET (06:01 GMT)
Indivior (LSE:INDV)
Historical Stock Chart
From Apr 2024 to May 2024
Indivior (LSE:INDV)
Historical Stock Chart
From May 2023 to May 2024